Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of DAWN will rise by +12.27% over the next 2 Weeks and hit $24.17 by Wednesday, May 6, 2026. In that time frame, DAWN's share price is expected to range between $20.55 and $27.54.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| May 6, 2026 | 22.07 | 26.07 | 29.55 |
| May 5, 2026 | 21.22 | 24.81 | 28.32 |
| May 4, 2026 | 21.09 | 24.87 | 28.47 |
| May 1, 2026 | 21.38 | 24.87 | 28.41 |
| Apr 30, 2026 | 20.49 | 24.16 | 27.72 |
| Apr 29, 2026 | 21.59 | 25.19 | 28.92 |
| Apr 28, 2026 | 20.20 | 23.93 | 27.57 |
| Apr 27, 2026 | 20.36 | 23.99 | 27.56 |
| Apr 24, 2026 | 20.39 | 23.99 | 27.71 |
| Apr 23, 2026 | 19.86 | 23.28 | 27.05 |
DAWN shares remained flat 0 in Friday, April 24, 2026's trading session, starting and closing at a previous close of $21.53 to move at $21.53. The stock demonstrated notable intraday movement (see DAWN's key stats for a full breakdown), fluctuating between $21.53 and $21.53, a 0 trading range. While recent weeks have seen some volatility, DAWN has managed to secure a +0.42% gain over the past 2 weeks. The neutral price movement was accompanied by increased trading volume, with approximately 2.97M shares changing hands, 889.52K more than the previous session. This amounted to $64.02M in total market activity.
Will DAWN Continue Its Upward Trend?
According to analyst ratings and projections for DAWN, Day One Biopharmaceuticals, Inc. shares are anticipated to increase by +27.13%, potentially reaching $29.55 per share by May 6, 2026. Short-term technical indicators currently suggest a neutral sentiment for DAWN. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 19 positive trading days within the past 30 sessions. Based on the DAWN stock forecast, now is a good time to buy DAWN stock because its current trading price is -17.42% below our predicted value, hinting at a possible overvaluation. For deeper insights, view our sentiment analysis on DAWN covering social and institutional perspectives.
DAWN Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into DAWN's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 77.69% to 81.30%) indicate the stock is in a strong bullish momentum phase. The 50-day RSI, at 70.08%, indicates significant medium-term strength. However, the 100-day RSI, at 64.24%, points to growing bullish momentum over the long term. Insights into DAWN's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Day One Biopharmaceuticals, Inc. Monthly Forecast 2026–2027
April 2026
According to our latest forecast models, Day One Biopharmaceuticals, Inc. (DAWN) is positioned to show a strong performance in April 2026. The price is predicted to move between $7.45 and $10.33, settling at an average of $8.83. This could translate to a -58.99% loss.
May 2026
Based on current market signals, Day One Biopharmaceuticals, Inc. is projected to trend may 2026. We forecast a trading range from $7.19 to $11.36, with a likely average price of $9.20. Investors could expect a potential return of -57.27%.
June 2026
Our predictive algorithms indicate Day One Biopharmaceuticals, Inc. stock may see a shift in June 2026. The expected range spans $7.88–$11.16, with an average target of $9.46. This represents a cautious outlook and a possible loss of -56.06%.
July 2026
Analyzing established trends, Day One Biopharmaceuticals, Inc. looks set to move in July 2026. Projections place the stock between $7.15 and $10.86, averaging around $8.86. This suggests a -58.85% loss from current levels.
August 2026
Market indicators suggest Day One Biopharmaceuticals, Inc. could experience notable changes during August 2026. Prices could fluctuate within $7.86 to $11.71, with a midpoint forecast of $9.78. The stock might deliver a -54.58% loss.
September 2026
Forecasting for September 2026, models estimate that Day One Biopharmaceuticals, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $6.76 and $11.25, averaging $9.17. This signals a cautious trajectory with potential returns around -57.41%.
October 2026
According to our latest forecast models, Day One Biopharmaceuticals, Inc. (DAWN) is positioned to show a strong performance in October 2026. The price is predicted to move between $5.52 and $10.69, settling at an average of $8.47. This could translate to a -60.66% loss.
November 2026
Based on current market signals, Day One Biopharmaceuticals, Inc. is projected to trend november 2026. We forecast a trading range from $7.22 to $11.79, with a likely average price of $8.90. Investors could expect a potential return of -58.66%.
December 2026
Our predictive algorithms indicate Day One Biopharmaceuticals, Inc. stock may see a shift in December 2026. The expected range spans $6.43–$10.03, with an average target of $8.17. This represents a cautious outlook and a possible loss of -62.05%.
January 2027
Analyzing established trends, Day One Biopharmaceuticals, Inc. looks set to move in January 2027. Projections place the stock between $7.21 and $11.01, averaging around $9.10. This suggests a -57.73% loss from current levels.
February 2027
Market indicators suggest Day One Biopharmaceuticals, Inc. could experience notable changes during February 2027. Prices could fluctuate within $5.94 to $10.88, with a midpoint forecast of $8.48. The stock might deliver a -60.61% loss.
March 2027
Forecasting for March 2027, models estimate that Day One Biopharmaceuticals, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $5.88 and $9.83, averaging $7.87. This signals a cautious trajectory with potential returns around -63.45%.
April 2027
According to our latest forecast models, Day One Biopharmaceuticals, Inc. (DAWN) is positioned to show a strong performance in April 2027. The price is predicted to move between $6.57 and $9.68, settling at an average of $8.14. This could translate to a -62.19% loss.
DAWN's history of dividends and stock splits also plays a role in long-term investor confidence.

